Holen Sie sich die Stockscreener-App
2.14
3.39%
-0.07
Schlusskurs vom Vortag:
$2.21
Offen:
$2.2
24-Stunden-Volumen:
1.77M
Relative Volume:
0.27
Marktkapitalisierung:
$602.04M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-225.14M
KGV:
-1.0918
EPS:
-1.96
Netto-Cashflow:
$-192.27M
1W Leistung:
-12.86%
1M Leistung:
-23.75%
6M Leistung:
+166.87%
1J Leistung:
+410.40%
1-Tages-Spanne:
$2.13
$2.205
1-Wochen-Bereich:
$2.13
$2.45
52-Wochen-Spanne:
$0.3546
$3.0699
Invivyd Inc Stock (IVVD) Company Profile
Firmenname
Invivyd Inc
Sektor
Branche
Telefon
(781) 819-0080
Adresse
209 CHURCH STREET, NEW HAVEN
Vergleichen Sie IVVD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IVVD
Invivyd Inc
|
2.135 | 623.19M | 0 | -225.14M | -192.27M | -1.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.01 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
751.87 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
815.87 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
362.61 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.31 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-22 | Eingeleitet | BTIG Research | Buy |
| 2025-11-25 | Herabstufung | D. Boral Capital | Buy → Hold |
| 2025-10-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-04-05 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-03-26 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-19 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-05-01 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Invivyd Inc Aktie (IVVD) Neueste Nachrichten
H.C. Wainwright reaffirms Buy rating on Invivyd stock ahead of key trial data - Investing.com
Analysts Are Bullish on These Healthcare Stocks: Invivyd (IVVD), Alignment Healthcare (ALHC) - The Globe and Mail
Invivyd partners with ski champion Lindsey Vonn on antibody education By Investing.com - Investing.com Nigeria
Invivyd prices $125M stock offering at $2.50 per share - MSN
Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates - sharewise.com
Invivyd partners with ski champion Lindsey Vonn on antibody education - Investing.com
Invivyd stock rises after partnering with Olympic champion Lindsey Vonn By Investing.com - Investing.com Canada
Invivyd partners with Lindsey Vonn to educate Americans on antibodies and disease prevention - marketscreener.com
Lindsey Vonn joins Invivyd to help Americans understand antibodies - Stock Titan
Invivyd stock maintains Buy rating at BTIG on Long COVID treatment potential By Investing.com - Investing.com Nigeria
Invivyd stock maintains Buy rating at BTIG on Long COVID treatment potential - Investing.com Nigeria
Invivyd to begin phase 2 trial of antibody therapy for long COVID - Investing.com Nigeria
Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026 - The Manila Times
Invivyd Initiates Phase 2 Trial for VYD2311 Targeting Long COVID Patients - Intellectia AI
Experimental COVID antibody trial targets Long COVID and vaccine injury by 2026 - Stock Titan
Short Interest in Invivyd, Inc. (NASDAQ:IVVD) Grows By 24.4% - MarketBeat
Bull Run: What is the target price for Invivyd Inc stockMarket Volume Summary & Safe Entry Trade Reports - baoquankhu1.vn
Invivyd, Inc.'s (NASDAQ:IVVD) Business Is Trailing The Industry But Its Shares Aren't - 富途资讯
Invivyd, Inc. (NASDAQ:IVVD) Given Average Rating of "Hold" by Brokerages - MarketBeat
Invivyd (IVVD) Reports Strong Q4 Growth, Advances COVID Antibody to Phase 3 - Insider Monkey
10 Best Penny Stocks to Buy for 2026 - Insider Monkey
MINISTRY OF HOME AFFAIRS OF THE SOCIALIST REPUBLIC OF VIETNAM - Bộ Nội Vụ
Invivyd (NASDAQ:IVVD) Trading Down 6.5%Time to Sell? - MarketBeat
Invivyd granted FDA fast track status for COVID therapy - MSN
Why Analysts See Invivyd (IVVD) Story Shifting After REVOLUTION Program And US$10 Target - Yahoo Finance
Invivyd (NASDAQ:IVVD) Trading Up 10.6%What's Next? - MarketBeat
Invivyd reports 25% growth in Q4 PEMGARDA revenue to $17.2 million - Investing.com Nigeria
Will Invivyd's DECLARATION Trial Send IVVD Stock Higher In 2026? - RTTNews
Invivyd (NASDAQ:IVVD) Shares Gap UpWhat's Next? - MarketBeat
Why Invivyd Inc. stock is trending among retail traders2025 Earnings Surprises & Free Reliable Trade Execution Plans - ulpravda.ru
Invivyd Reports Strong PEMGARDA Growth and Advances VYD2311 - TipRanks
Invivyd, Inc. Reports Preliminary Q4 2025 Revenue of $17.2 Million and Announces Key Clinical Developments - Quiver Quantitative
Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights - The Manila Times
Star TribuneInvivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights - FinancialContent
Invivyd, Inc. (IVVD): Advancing RSV antibody VBY329 amid analyst downgrade - MSN
Invivyd (NASDAQ:IVVD) Stock Price Down 5.5%Here's What Happened - MarketBeat
Aug Gainers: Why Heiwa Real Estate Co Ltd HZJ stock appears on watchlistsDividend Hike & Growth Focused Entry Reports - moha.gov.vn
Invivyd Inc. | Latest News & Innovations - shababeek.org
BTIG initiates Invivyd (IVVD) coverage, cites VYD2311’s superior market potential over Pemgarda - MSN
BTIG Initiates Invivyd (IVVD) Coverage, Cites VYD2311’s Superior Market Potential Over Pemgarda - Insider Monkey
Invivyd (NASDAQ:IVVD) Trading Down 3.7%Here's Why - MarketBeat
Is Invivyd Inc. stock supported by strong fundamentalsChart Pattern Recognition & Minimal Risk High Reward - bollywoodhelpline.com
Does Invivyd’s (IVVD) Index Debut Reveal a Turning Point in Its Biotech Credibility? - Yahoo Finance
BTIG Reiterates Invivyd (IVVD) Buy Recommendation - Nasdaq
BTIG Research Upgrades Invivyd (NASDAQ:IVVD) to Strong-Buy - MarketBeat
FDA grants fast track designation for Invivyd’s COVID antibody By Investing.com - Investing.com Nigeria
Invivyd begins phase 3 trial of COVID prevention antibody VYD2311 By Investing.com - Investing.com Nigeria
US OPEN: Markets wobble amid low volumes and resilient GDP (23.12.2025) - XTB.com
Is Invivyd’s (IVVD) Index Debut Quietly Reframing Its Long-Term Biotech Positioning? - simplywall.st
Invivyd wins FDA fast track tag for COVID drug (IVVD:NASDAQ) - Seeking Alpha
Finanzdaten der Invivyd Inc-Aktie (IVVD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Invivyd Inc-Aktie (IVVD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| MCLAUGHLIN KEVIN F | Director |
Nov 19 '25 |
Buy |
2.50 |
50,000 |
125,000 |
50,000 |
3.27%
2.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):